Demant CEO won't rule out dismissals following divestment of implant division

The 700 people employed at Demant’s surgical division, Oticon Medical, have an uncertain future ahead after the parent company announced its intention to sell the unit to Cochlear. CEO Søren Nielsen says some people might be transferred and others reshuffled within Demant, but he won’t reject having to resort to dismissals.
Photo: Kenneth Lysbjerg Koustrup/Jyllands-Posten/Ritzau Scanpix
Photo: Kenneth Lysbjerg Koustrup/Jyllands-Posten/Ritzau Scanpix
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

If any worried faces were detected this morning among the around 700 people working at the implant division of hearing aid manufacturer Demant, it is well understood why.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading